Wet AMD Surgery: When Is It Necessary?

Anti‑VEGF injections remain the gold‑standard treatment for wet age‑related macular degeneration (AMD), but surgery becomes a consideration when injections no longer control the disease or when specific complications arise. Below are the primary scenarios in which a retinal specialist may recommend surgical intervention.

1. Persistent Fluid and Macular Edema

If repeated anti‑VEGF injections fail to resolve subretinal or intraretinal fluid, surgery may be needed to drain the fluid and relieve mechanical stress on the photoreceptors.

2. Subretinal Neovascularization (SRN)

When abnormal vessels grow beneath the retina and leak blood or fluid, surgical removal of the neovascular membrane and associated scar tissue can preserve remaining vision.

3. Refractory Choroidal Neovascularization (CNV)

Extensive or recurrent CNV that does not respond to anti‑VEGF therapy may be addressed with submacular surgery or other techniques aimed at excising the lesion.

4. Vitrectomy

A pars plana vitrectomy clears vitreous hemorrhage, removes epiretinal membranes, or relieves vitreomacular traction that compromises vision. It is often combined with membrane peeling or endolaser.

5. Macular Translocation Surgery

In highly selected cases with severe subfoveal scarring, the neurosensory retina is rotated to a healthier retinal pigment epithelium (RPE) bed. This complex procedure is reserved for patients who have exhausted all other options.

6. Retinal Prosthesis (Implant) Surgery

For end‑stage disease with profound central vision loss, devices such as the Argus II or newer subretinal implants can provide rudimentary form perception and light localization.

7. Corneal Endothelial Transplantation (DMEK/DSAEK)

Although not a direct AMD treatment, Descemet membrane endothelial keratoplasty may improve visual acuity in patients who have concurrent corneal endothelial dysfunction (e.g., Fuchs dystrophy) that limits the benefit of retinal therapy.

Decision‑Making

The choice to operate depends on disease stage, visual potential, systemic health, and a careful risk–benefit analysis. A detailed discussion with a vitreoretinal surgeon is essential to tailor the optimal plan for each patient.